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Abbreviations:34 
CBA  cytometric bead array 35 
CRP - C reactive protein 36 
COX2  Cyclooxygenase 2 37 
DC  Dendritic Cell 38 
EP4 - Prostaglandin E2 receptor 4 39 
LPS  Lipopolysaccharide 40 
ILT - Immunoglobulin-like transcript 41 
p38-MAPK - p38 mitogen-activated protein kinase 42 
PD-L - Programme-death ligand 43 
PGE2 - Prostaglandin E2 44 
PV  perivascular infiltrate 45 
SASP - senescence associated secretory phenotype 46 
TAF - telomere-associated DNA-damage  47 
Tregs - T regulatory cells  48 
TRM - T resident-memory cells  49 
VZV - Varicella Zoster Virus  50 
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Abstract: 51 
We have previously shown that healthy older adults exhibit reduced cutaneous immune 52 
responses during a varicella zoster virus (VZV) antigen challenge that correlated with a non-53 
specific inflammatory response to the injection itself.  54 
Here we found that needle damage during intradermal injections in older adults led to an 55 
increase in the number of cutaneous senescent fibroblasts expressing CCL2, resulting in the 56 
local recruitment of inflammatory monocytes. These infiltrating monocytes secreted 57 
prostaglandin E2 (PGE2) that inhibited resident memory T cell (TRM) activation and 58 
proliferation. Pre-treatment of older subjects with a p38-MAPK inhibitor in vivo decreased 59 
CCL2 expression and inhibited monocyte recruitment and secretion of PGE2. This coincided 60 
with an increased response to VZV antigen challenge in the skin.  61 
Our results point to a series of molecular and cellular mechanisms that link cellular 62 
senescence, tissue damage, excessive inflammation and reduced immune responsiveness 63 
in human skin and demonstrate that tissue-specific immunity can be restored in older adults 64 
by the short-term inhibition of inflammatory responses.  65 
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Introduction: 66 
Immunity decreases during ageing as demonstrated by the increased susceptibility to 67 
infections including pneumonia and influenza, re-activation of latent infections such as 68 
varicella zoster virus (VZV), decreased vaccine efficacy and increased incidence of cancer1, 69 
2, 3. In addition, there is an increase in low grade systemic inflammation in older humans 70 
termed inflammageing, that is characterised by high serum levels of the inflammatory 71 
cytokines IL-6, IL-1 , TNF  and C reactive protein (CRP)4. This elevated expression of 72 
inflammatory proteins is a strong predictor for frailty and mortality5, 6. Mechanisms that 73 
contribute to inflammageing are multifactorial, and include increased numbers of senescent 74 
cells (which secrete many inflammatory proteins as part of the senescence associated 75 
secretory phenotype (SASP), increased gut permeability and subsequent lipopolysaccharide 76 
(LPS; a TLR4 ligand) exposure, expression of damage-associated molecular pattern 77 
molecules (DAMPs) and failure of immune resolution7.   78 
Cutaneous recall antigen challenge is often used as a measure of effective immunity. Older 79 
individuals have reduced responses to challenge with various recall antigens including 80 
tuberculin PPD, Candida albicans and varicella zoster virus (VZV) antigens 8, 9, 10, 11. We 81 
showed previously that this decrease was a result of heightened inflammatory responses in 82 
the skin of older individuals during immune challenge and not from changes in antigen-83 
specific circulating or skin resident-memory T cells (TRM)
12. However, the mechanism by 84 
which inflammation inhibits antigen-specific immunity in the skin is unknown.  85 
Here we show that when challenging old individuals in the skin with VZV antigens, the tissue 86 
damage caused by the injection of the VZV antigen itself induces senescent fibroblasts to 87 
recruit CCR2+CD14+ monocytes from the circulation. These infiltrating monocytes express 88 
cyclooxygenase 2 (COX2) and produce prostaglandin E2 (PGE2) that inhibits TRM activation 89 
and proliferation. Pre-treatment of older individuals with and oral p38 MAPK inhibitor 90 
inhibited monocyte recruitment and PGE2 production during the immune response to VZV. 91 
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This resulted in a significantly enhanced VZV-specific mediated delayed type 92 
hypersensitivity responses associated with the activation and expansion of T cell numbers in 93 
the skin. These data identify a broad mechanism by which even mild tissue damage may 94 
induce inflammation in the tissues of older individuals that can inhibit immunity. An important 95 
consideration is whether the short-term blockade of inflammation would enhance the 96 
immune responses of older humans at early stages of (pathogen) infection where the 97 
infectious agent may induce damage and excessive inflammation that may retard 98 
subsequent immune responsiveness.  99 
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Results: 100 
Inappropriate response to tissue damage in the skin during ageing 101 
Old ( 65 years) and young (<40 years) individuals were recruited for this study, donor 102 
characteristics can be found in Supplementary Table 1. Although there were more females in 103 
the older adult group, there was no difference in response between the different genders 104 
within this group (Extended Figure 1A). Volunteers were injected intradermally with VZV skin 105 
test antigen in one arm (for the clinical score) and with saline (0.9% NaCl) in the other arm 106 
as a control. 5mm biopsies were collected from the injection sites 6 hours post-injection and 107 
compared to biopsies of normal (unmanipulated) skin (Figure 1A). The VZV injection site 108 
was assessed for clinical score 72 hours after injection and the induration, palpability and 109 
change in erythema from baseline were measured and scored, as described before11. We 110 
showed previously that mononuclear phagocyte numbers were increased at the site of saline 111 
injection in old but not young subjects and that this accumulation negatively correlated with 112 
the magnitude of antigen-specific responses induced in the contralateral arm of the same 113 
individual9. Multiparametric flow cytometry on disaggregated skin biopsies from old donors 114 
showed no change in the number of CD11c+, CD1c+ or BDCA-3+ dendritic cells (DC) in 115 
response to saline challenge (Extended Data Figure 2A-D). Neutrophils, as determine by 116 
CD66b expression by immunofluorescence or CD45+lineage-CD16+HLA-DR- by flow 117 
cytometry were observed at very low numbers in normal skin which did not significantly 118 
change after saline injection (Extended Data Figures 3A and B and 4A and B). These data 119 
implies that the increase in mononuclear phagocytes was due to accumulation of 120 
monocytes. 121 
To enumerate the changes in monocyte numbers following saline injection we assessed 122 
paired samples and expressed data as delta change from normal skin. This was to mitigate 123 
against inter-personal variation in the magnitude of responses observed (Extended Data 124 
Figure 5A). CD14 was used to identify monocytes in these experiments as it is expressed by 125 
the majority of peripheral blood monocytes (classical and intermediate) while CD16+CD14- 126 
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monocytes were relatively rare in the skin (Extended Data Figure 4A). There was a 127 
significant increase in CD14+ cells in saline injected skin at 6 hours post-injection (Figure 1B 128 
and 1C). We next investigated the expression of CCR2, a chemokine receptor for CCL2, 129 
which is highly expressed by CD14+ monocytes13, 14. There was a significant increase in 130 
number of CD14+CCR2+ cells in saline injected skin as compared to normal skin in old but 131 
not young subjects (Figure 1C, larger images can be seen in Supplementary Figure 1A and 132 
B). This response to saline was transient as by 24 hours post-injection similar frequency 133 
frequencies of monocytes were detected in normal and saline-injected skin (Extended Data 134 
Figure 5B). Multiparametric flow cytometry analysis of normal and saline biopsies, using the 135 
gating strategy shown in Extended Data Figure 4A, confirmed that there was a significant 136 
increase in CD14+ and CCR2+CD14+ cells in old saline-injected skin (Figure 1D). We also 137 
observed a smaller population of HLA-DR+ cells that were CCR2+CD14- in normal skin, 138 
however this population did not significantly change after saline injection (Extended Data 139 
Figure 4C). Further phenotyping of the HLA-DR+ population with CD86, CLA, SLAN, CD16, 140 
CX3CR1 showed that their expression was similar before and after saline injections. The 141 
only population that changed in the old subjects after saline-injection were those that 142 
expressed CD14 and CCR2, suggesting that it was an increase in the number of 143 
CD14+CCR2+ monocytes rather than a change in their phenotype (Extended Data Figure 144 
4D-F).  145 
To investigate whether this inflammatory response after saline injection in older humans was 146 
due to injection with sodium chloride itself or a response to needle injury, we performed 147 
intradermal injections with the same volume of air instead of saline (20 l). Air injection also 148 
induced a significant increase in the number of monocytes at the site of challenge in old but 149 
not young adults compared to normal skin (Extended Data Figure 5C). The accumulation of 150 
monocytes was also observed at six hours at the site of VZV injection in old but not young 151 
adults (Figure 1E). Taken together these data suggest that old subjects have a heightened 152 
inflammatory response to mild skin injury that is not observed in young individuals.  153 
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We previously showed that >85% of older individuals have a low VZV response (clinical 154 
score between 0-3), while >85% of young individuals have a score of between 3-108, 12. 155 
However, a small proportion of older people (~15%) show good cutaneous VZV 156 
responsiveness (score above 3), a group we designated as old responders. To assess 157 
whether the CD14+ monocyte infiltration was a characteristic of all aged individuals or only 158 
those with reduced VZV-specific immunity, we investigated the accumulation of these cells 159 
after saline in old VZV responders (red circles) and low responders (filled circles; Fig1F). An 160 
increase in monocytes at the site of challenge was only observed in old individuals with a 161 
low clinical score while old individuals with a good clinical score behaved similarly to young 162 
individuals with low monocyte infiltration. Taken together, there was a significant negative 163 
correlation between the fold change in CD14+ monocytes in response to saline challenge 164 
and the VZV clinical score (R=-0.38 and p=0.04; Figure 1E), a similar correlation was 165 
observed between CD14+CCR2+ cells and the clinical score (Supplementary Figure 2).  166 
Collectively this indicates that the early recruitment of monocytes to the site of skin challenge 167 
in old people was associated with decreased antigen-specific immunity. 168 
 169 
Senescent stromal cells contribute to recruitment of monocytes in the old. 170 
We hypothesised that the increase in CD14+ cells in the skin was due to recruitment of 171 
circulating monocytes, since CCR2+ expression supported the possibility of recruitment in 172 
response to CCL2. The alternative explanation that this was a consequence of the 173 
proliferation of local tissue-resident macrophages (identified as CD163+), however this was 174 
not observed (Extended Data Figure 6A-C). This is in line with murine studies showing 175 
dermal macrophages are constantly replenished from the monocyte pool rather than 176 
proliferation15. We first investigated the activation status of the dermal endothelium to 177 
determine whether it was permissive for monocyte recruitment. CD62E, also known as E-178 
selectin, was used as a marker of activated endothelium as it binds to sialylated 179 
carbohydrates expressed on leukocytes and facilitates their extravasation into the tissue.  180 
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Saline-injected skin of old but not young adults exhibited increased CD62E expression on 181 
the CD31+ endothelium when compared to normal skin (Figure 2A and B). Furthermore, 182 
transcriptional analysis of skin biopsies indicated that there was increased expression of a 183 
range of genes encoding monocyte chemoattractants including CCL2 (one of the main 184 
monocyte chemoattractants), CXCL10, CXCL2 and CXCL1 in old but not young in response 185 
to saline injection (Figure 2C). Increased CCL2 expression in saline-injected old skin was 186 
confirmed by immunofluorescence staining of skin sections (Figure 2D). As expected, there 187 
was no significant change in the expression of CCL2 cells in young skin after saline-injection 188 
(Figure 2D). 189 
We next examined the source of monocyte chemoattractants and found that resident 190 
mononuclear phagocytes were not the main source of CCL2 (Extended Data Figures 7A and 191 
B). Using FSP-1 as a marker of fibroblasts, we found that there was a significant increase in 192 
the number of fibroblasts expressing CCL2 in the skin of old subjects after saline injection as 193 
compared to normal un-injected skin (Figure 2E and F, larger images can be seen in 194 
Extended Data Figure 7C). It is known that fibroblasts can produce CCL216. We and others 195 
have shown that there are increased numbers of senescent fibroblasts in the skin of older 196 
humans16, 17, 18 and CCL2 is a known component of the senescence associated secretory 197 
phenotype (SASP)19. Indeed, using p16 as a marker of senescence we found that 198 
FSP1+p16+ fibroblasts were the main source of CCL2 after saline injection of old donors 199 
(Figure 2G and H, larger images can be seen in Extended Data Figure 7D). Senescent 200 
fibroblasts made up 54.1% of CCL2+FSP1+ cells in normal skin which increased to 66.8% in 201 
saline-injected skin (Extended Data Figure 7E). Although some non-senescent fibroblast 202 
evidently expressed CCL2, our previous data showed that senescent fibroblasts produce 203 
significantly more CCL2 than the non-senescent fibroblasts16. Therefore, the early 204 
production of SASP-related mediators by senescent fibroblasts after saline injection 205 
(including CCL2) may lead to the recruitment of inflammatory monocytes to the site of skin 206 
challenge. This interaction between senescent cells and monocyte recruitment is supported 207 
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indirectly by the significant correlation between the number of senescent fibroblasts present 208 
in the skin, as determined by telomere-associated DNA-damage (TAF) foci positive FSP-1+ 209 
cells (representative staining can be found in Extended Data Figure 8),  present in the skin 210 
and the extent of CD14+ monocyte infiltration after saline injection (Fig. 2I). 211 
 212 
Monocytes inhibit TRM proliferation through production of Prostaglandin E2. 213 
We next investigated the mechanisms by which the recruitment of monocytes reduced 214 
antigen-specific immunity in old subjects. We first assessed inhibitory pathways in normal 215 
and saline injected skin by RNAseq. We found that saline injection in old individuals 216 
increased the expression of a number of immunoglobulin-like transcript (ILT) receptors such 217 
as LILRB3 (ILT5), LILRB2 (ILT4), LILRA2 (ILT1), LILRB4 (ILT3) and LILRB1 (ILT2), 218 
inhibitory ligands such as CD274 (programme-death ligand 1; PDL-1) and PDCD1LG2 (PDL-219 
2), ligand for the T cell receptor TIGIT and PVR, as well as inducible COX2 enzyme 220 
(PTGS2) (Figure 3A).   221 
PTGS2 (encoding COX2) was one of the most highly upregulated genes in saline-injected 222 
skin of the old subjects9 and elevated COX2 expression following saline injection was 223 
confirmed at the protein level by immunohistology (Figure 3B and C, larger images can be 224 
seen in Extended Data Figure 9A). When staining for COX2 was performed in combination 225 
with CD14 there was a significant increase in CD14+COX2+ cells in saline injected as 226 
compared to normal skin (Figures 3D). There was no significant difference in the number of 227 
CD14-COX2+ cells (Extended Data Figure 9B), indicating that this increase in COX2 was 228 
specific to CD14+ monocytes. 229 
To demonstrate that COX2 expressing monocytes can inhibit the activation of CD4+ T cells, 230 
we first induced COX2 expression in monocytes isolated from peripheral blood by 231 
stimulation with LPS (1ng/ml) for 3 hours.  LPS treatment significantly increased COX2 232 
expression as compared to untreated controls (Supplementary Figure 3)20, 21. Unstimulated 233 
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and LPS-stimulated monocytes were then co-cultured with autologous peripheral CD4+ T 234 
cells in the presence of anti-CD3 and IL-2 and proliferation was assessed after four days. 235 
Stimulated monocytes inhibited CD4+ T cell proliferation as compared to control 236 
(unstimulated) monocytes (Figure 3E-F). However, production of the cytokines IFNy, IL-2 237 
and IL-10 was not affected at day 4 post-culture. The COX2-specific inhibitor NS-398 was 238 
then used to determine if COX2 expression was involved in the inhibition of CD4+ T cell 239 
proliferation. Treatment with NS-398 led to a significant increase in the proliferation of the 240 
CD4+ T cells (Figure 3G and H and Supplementary Figure 4A). COX2 is involved in the 241 
production of a range of lipid mediators, the most common being PGE2
22. To establish if 242 
PGE2 was involved in the inhibition of CD4
+ T cell proliferation, we blocked the receptor for 243 
PGE2, EP4, on CD4
+ T cells using the inhibitor MF-498. Blockade of PGE2 signalling also 244 
significantly increased the proliferation of the CD4+ T cells in the presence of inflammatory 245 
monocytes (Figure 3H and I and Supplementary Figure 4B). To confirm that PGE2 did not 246 
alter the monocyte phenotype we cultured monocytes with PGE2 and assessed their 247 
inhibitory receptor (CD112, CD155, Galectin 9, ILT3 and PDL-1, PDL-2) expression and 248 
cytokine production. We did not observe any significant effects of PGE2 treatment on the 249 
expression of these receptor in monocytes, confirming that PGE2 directly affected CD4+ T 250 
cells. To assess if the above observations were relevant in the skin of old donors in vivo, we 251 
investigated Prostaglandin E2 receptor 4 (EP4) expression by skin-resident CD4+CD69+ TRM 252 
cells in older volunteers (Figure 4A). The majority of CD4+ TRM expressed EP4 (81.2%), 253 
indicating that they have the capacity to respond to PGE2 produced by monocytes. We next 254 
assessed the co-localisation of CD14+ monocytes and CD4+TRM cells in normal and saline 255 
injected skin from old subjects. In normal skin, CD14+ monocytes were on average 15.86 m 256 
away from CD4+ TRM, however after saline injection the monocytes were significantly closer 257 
to the CD4+ TRM (9.47 m; Figure 4B and C). This increased proximity was likely due to 258 
increase in the number of monocytes in the skin after saline injection. To confirm that 259 
monocytes have the ability to suppress skin CD4+ TRM proliferation, CD4
+ TRM were isolated 260 
from the skin using suction blister technology as described previously (Figure 4D)11. Skin 261 
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CD4+ TRM cells were then pre-labelled with CellTrace Violet and stimulated with CD3 and IL-262 
2 in the presence of either stimulated or unstimulated monocytes for four days. We observed 263 
a significant reduction in CD4+ TRM cell proliferation in the presence of stimulated as 264 
compared to unstimulated monocytes (Figure 4E and F) supporting the hypothesis that 265 
COX2+ monocytes have the capability to suppress TRM proliferation.  266 
 267 
p38 MAP kinase inhibition significantly reduces CCL2 production from senescent 268 
fibroblasts.269 
We showed previously that treatment of old subjects with the anti-inflammatory p38-MAPK 270 
inhibitor, Losmapimod, significantly enhanced the response to VZV antigens in the skin9. To 271 
investigate if p38-MAPK inhibition altered CCL2 production and inflammatory monocyte 272 
recruitment in the skin, RNAseq analysis was performed on biopsies collected from normal 273 
skin and from skin 6 hours after saline injection with saline both before and after 274 
Losmapimod treatment (study design Figure 5A). We stratified our subjects in the RNAseq 275 
analysis according to the extent of clinical score improvement. The individuals that had no 276 
improvement in clinical score are represented as white, and those who had the biggest 277 
improvement in clinical score after Losmapimod treatment represented by dark green 278 
(Figure 5B). A list of all differentially expressed genes can be found in Supplementary Table 279 
4. Saline injection resulted in a large pro-inflammatory response with a significant increase in 280 
the expression of inflammatory associated genes such as CCL2, CAFCL8, FOSL1, IL1B and 281 
TREM1 at 6 hours pre-Losmapimod treatment (Figure 5C). This response to saline was 282 
reduced after Losmapimod pre-treatment (Figure 5C) and of the top six significantly 283 
upregulated genes in saline-injected skin as compared to normal were no longer significantly 284 
different post-Losmapimod treatment (Extended Data Figure 10A).  In addition, there was a 285 
strong trend towards reduction in saline-specific gene expression after Losmapimod 286 
treatment (p=0.06; Extended Data Figure 10B).  RNAseq analysis showed that the 287 
expression of monocyte chemoattractants (induced in response to saline injection) was 288 
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reduced post-Losmapimod treatment (Extended Data Figure 10E). However, the reduction in 289 
genes specific to saline response in old (saline-specific gene expression) did not correlate 290 
with improvement in clinical score (Extended Data Figure 10C) and the same was observed 291 
with CCL2 (Extended Data Figure 10D).  292 
After Losmapimod treatment there was a significant reduction in the number of CCL2+ cells 293 
and the number of CCL2+ senescent (p16+FSP-1+) fibroblasts (Figures 5D, 5E). Treatment of 294 
senescent dermal fibroblasts with Losmapimod in vitro significantly reduced their CCL2 295 
production, suggesting Losmapimod could have a direct effect on senescent fibroblast in 296 
vivo (Extended Data Figure 10F). As a result of the reduced CCL2 production, monocyte 297 
infiltration in saline injected skin was significantly decreased post-Losmapimod treatment 298 
(Figure 5F). A significant reduction in the number of monocytes after Losmapimod treatment 299 
was observed when VZV injected skin (6 hour post-injection) was assessed (Figure 5G). 300 
Together, these data indicate that p38-MAPK inhibition significantly reduces CCL2 301 
production from senescent fibroblasts reducing the accumulation of monocytes at sites of 302 
saline or VZV antigen challenge in the skin.  303 
 304 
p38 MAP kinase inhibition significantly inhibits PGE2 that restores T cell proliferation. 305 
COX2 expression has been shown to be regulated downstream of p38-MAPK signalling20, 23, 306 
implying that Losmapimod may act by inhibiting COX2 expression in vivo. To test this, we 307 
performed Western blot analysis of LPS activated monocytes in the presence or absence of 308 
Losmapimod. Losmapimod significantly decreased the LPS induced expression of phopho-309 
p38 MAPK and COX2 in vitro (Figures 6A and B). In addition, PGE2 production was also 310 
significantly decreased after Losmapimod treatment (Figure 6C).  Furthermore, the addition 311 
of Losmapimod to co-cultures of CD4+ T cells that were stimulated in the presence of LPS 312 
treated monocytes (Figure 6D and E and Supplementary Figure 4C) enhanced their 313 
proliferation to a similar extent to that observed after direct COX2 or EP4 inhibition (Figure 314 
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3G and H). In line with these observations, the increase in CD14+COX2+ cells after saline 315 
injection was also inhibited after post-Losmapimod treatment in vivo (Figure 6F). These data 316 
collectively suggest that in vivo Losmapimod can restore CD4+ T cell responses in part 317 
through the inhibition of COX2 expression. 318 
 319 
p38 MAP kinase inhibition significantly increases T cell infiltration into the site of VZV 320 
challenge.321 
We assessed the clinical score of 42 old subjects after VZV antigen challenge both before 322 
and after Losmapimod treatment. We confirmed and extended our previous observations 323 
that treatment with Losmapimod significantly increased VZV clinical score (n=42; Figure 7A). 324 
No difference was observed between male and female volunteers in their response to 325 
Losmapimod treatment (Extended Data Figure 1B). Losmapimod treatment also significantly 326 
decreased serum CRP in all individuals, irrespective of whether they showed an improved 327 
skin response to VZV challenge (Figure 7B).  328 
We previously identified a significant association between the clinical score after VZV 329 
antigen challenge and the accumulation of T cells and DCs at the site of injection8, 9. VZV 330 
challenged skin sections collected pre- and post-Losmapimod were stained for CD4 or CD8, 331 
Ki67 and CD11c (Figure 7C and D). We found that Losmapimod pre-treatment was 332 
associated with a significant increase in CD4+ (Figure 7E) and CD8+ (Figure 7G) T cell 333 
accumulation in the skin 7 days after VZV injection. The increased number of CD4+ and 334 
CD8+ T cells in perivascular infiltrates was associated with an increased proliferation of 335 
these cells in situ indicated by Ki67 expression (Figures 7F and H)12. Concurrently there was 336 
also an increase in CD11c+ DCs in the VZV-injected skin post-Losmapimod (Figure 7I), 337 
suggesting there was an increase in T cell and DC clusters as observed previously9. Taken 338 
together our data show that short-term blockade of inflammation using the p38 MAP kinase 339 
inhibitor Losmapimod can significantly enhance the cutaneous immune response to antigen 340 
challenge in older adults.  341 
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Discussion: 342 
We demonstrate that senescent fibroblasts in the skin of old subjects secrete an array of 343 
chemokines including CCL2 in response to tissue injury, such as that induced by injecting 344 
saline, VZV or air. This leads to recruitment of inflammatory monocytes into the skin that 345 
inhibit skin TRM activation in part by secreting lipid mediators such as PGE2 via a COX2-346 
dependant pathway. However, short-term systemic p38-MAPK blockade (that also inhibits 347 
COX2) leads to a significant reduction in CCL2, infiltrating monocytes and reduced PGE2 348 
expression in response to injection of saline or VZV antigens. This results in significant 349 
improvement of VZV-specific cutaneous T cell responses (Figure 8).  350 
Ageing leads to the accumulation of senescent cells in many tissues including the skin16, 18. 351 
Therefore the recruitment of inflammatory monocytes by senescent fibroblasts may also 352 
contribute to age-related decreased immune responses in other organs. The significant 353 
correlation between the number of senescent dermal fibroblasts and the extent of CD14+ 354 
monocyte infiltration indirectly supports the interaction between these cells. Although the 355 
abundance of senescent cells increases in the skin during ageing16, 17, 18, there is no overt 356 
expression of inflammatory mediators in un-manipulated skin of old subjects12. This suggests 357 
that at the steady state, the propensity to mount an inflammatory SASP response is inhibited 358 
by the increased numbers of Foxp3+ T regulatory cells (Tregs) and PD-1 expressing TRM 359 
cells observed in the skin of older people10, 12. Thus, the breakdown of homeostasis induced 360 
by tissue injury may override pre-existing inhibitory processes.  361 
PGE2 has disparate roles in immune responses as it has been shown to be pro-inflammatory 362 
(causing oedema formation and pain) as well as contributing to resolution of inflammation22. 363 
PGE2 can also suppress CD8
+ T cells and may delay viral clearance24. Here we show that 364 
PGE2 inhibits CD4
+ T cell and TRM proliferation in vitro thus confirming previous data 
25. 365 
Furthermore, PGE2 has been shown to induce the expansion and increase the function of 366 
Foxp3+ Tregs26, 27 which may explain why these cells increases in the skin during ageing10, 28. 367 
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In addition, PGE2 may promote immunosuppression by increasing expression of the anti-368 
inflammatory cytokine IL-10 by mononuclear phagocytes29, 30. PGE2 can also have negative 369 
effects on DCs31. As CD11c+ DCs increase in the skin post-Losmapimod treatment, we 370 
cannot rule out that PGE2 may also have an inhibitory effect on DCs in the skin. 371 
We have confirmed previous observations that monocytes can inhibit antigen-specific 372 
responses32, 33. This is may be relevant for the Sars-Cov-2 pandemic which 373 
disproportionately affects older subjects34, since inflammatory monocytes have been found 374 
in the lungs of patients with severe COVID-19 disease35 and these cells may inhibit the 375 
function of virus-specific T cells, as described above.  376 
Excessive inflammation has been shown to inhibit antigen-specific immunity36 and reduce 377 
vaccination efficacy in many different contexts37, 38, 39. In addition to p38-MAPK inhibition, 378 
other drugs such as mTOR inhibitors, have been used to enhance immunity after vaccination 379 
in older individuals40. Furthermore, COX2 inhibitors have shown promise at improving DC-380 
based vaccine efficacy in mouse models of cancer41. The data presented here suggests that 381 
COX2 inhibitors which are routinely used in other inflammatory conditions could be used to 382 
improve immunity in older people. Thus, the inhibition of age associate inflammation in older 383 
subjects may be a promising approach for enhancing immunity to infection, cancer therapy 384 
and vaccination during ageing.  385 
 386 
Acknowledgements:  387 
Funding: This work was funded by the Medical Research Council (MRC) Grand Challenge 388 
in Experimental Medicine (MICA) Grant (MR/M003833/1 to ANA, MVS, TF, and NM), MRC 389 
New Investigator award (G0901102 to MVS), Dermatrust and MRC responsive mode grant 390 
(MR/T030534/1 to ANA), British Skin Foundation (BSF5012 to ANA), Institute Strategic 391 
Programme Grant funding from the Biotechnology and Biological Sciences Research 392 
Council (BBS/E/D/20002173 to TF and NM) and National Institute for Health Research 393 
University College London Hospitals Biomedical Research Centre. 394 
  ES Chambers et al 
 
28 | P a g e  
 
We thank Dr. Iain Laws, Dr. Ruchira Glaser, Dr Lea Sarov-Blat and Dr. Robert Henderson at 395 
GSK, Dr Veronique Birault at the Francis Crick Institute and Professor Mahdad Noursadeghi 396 
at University College London for support in developing this project.  We are also grateful to 397 
Glaxo-Smith Kline for providing the drug Losmapimod (MICA agreement with the MRC) and 398 
to the Losmapimod team at GSK for organizing the dispatch of the clinical supply of the drug 399 
in this Investigator Led study. We would especially like to thank the blood and skin donors 400 
who volunteered for this study and to our research nurses Ms Megan Harries-Nee and Ms. 401 
Michelle Berkley for their outstanding work 402 
 403 
Author contribution:  404 
ESC designed, performed experiments and wrote the manuscript. MVS was involved in the 405 
overall design of the study, experimental design and wrote the manuscript. HT and OPD 406 
performed the experiments. BBS, NAM and TCF performed the bioinformatic analysis of the 407 
RNA-seq samples. PS and JG performed clinical procedures and sample collection. MR was 408 
the clinical lead for the study and was involved with scientific discussions. DG advised 409 
experimental design for COX2 and PGE2 work. ANA was involved in the overall design of 410 
the study, initiated and coordinated the collaborative interaction between the different 411 
research groups, interpreted the data, contributed writing and edited the manuscript. 412 
 413 
Competing interests: The authors declare that they have no competing interests related to 414 
this work.   415 
  ES Chambers et al 
 
29 | P a g e  
 
References: 416 
1. Gavazzi, G. & Krause, K.H. Ageing and infection. Lancet Infect Dis 2, 659-666 417 
(2002). 418 
 419 
2. Diffey, B.L. & Langtry, J.A. Skin cancer incidence and the ageing population. Br J 420 
Dermatol 153, 679-680 (2005). 421 
 422 
3. Ciabattini, A. et al. Vaccination in the elderly: The challenge of immune changes with 423 
aging. Semin Immunol 40, 83-94 (2018). 424 
 425 
4. Franceschi, C., Garagnani, P., Vitale, G., Capri, M. & Salvioli, S. Inflammaging and 426 
'Garb-aging'. Trends in endocrinology and metabolism: TEM 28, 199-212 (2017). 427 
 428 
5. Furman, D. et al. Expression of specific inflammasome gene modules stratifies older 429 
individuals into two extreme clinical and immunological states. Nature medicine 23,430 
174-184 (2017). 431 
 432 
6. Dinh, K.M. et al. Low-grade inflammation is negatively associated with physical 433 
Health-Related Quality of Life in healthy individuals: Results from The Danish Blood 434 
Donor Study (DBDS). PLoS One 14, e0214468 (2019). 435 
 436 
7. Chambers, E.S. & Akbar, A.N. Can blocking inflammation enhance immunity during 437 
aging? J Allergy Clin Immunol 145, 1323-1331 (2020). 438 
 439 
8. Agius, E. et al. Decreased TNF-alpha synthesis by macrophages restricts cutaneous 440 
immunosurveillance by memory CD4+ T cells during aging. The Journal of 441 
experimental medicine 206, 1929-1940 (2009). 442 
 443 
9. Vukmanovic-Stejic, M. et al. Enhancement of cutaneous immunity during aging by 444 
blocking p38 mitogen-activated protein (MAP) kinase-induced inflammation. J Allergy 445 
Clin Immunol 142, 844-856 (2018). 446 
 447 
10. Vukmanovic-Stejic, M. et al. The kinetics of CD4+Foxp3+ T cell accumulation during 448 
a human cutaneous antigen-specific memory response in vivo. J Clin Invest 118,449 
3639-3650 (2008). 450 
 451 
11. Akbar, A.N. et al. Investigation of the cutaneous response to recall antigen in humans 452 
in vivo. Clin Exp Immunol 173, 163-172 (2013). 453 
 454 
12. Vukmanovic-Stejic, M. et al. The Characterization of Varicella Zoster Virus-Specific T 455 
Cells in Skin and Blood during Aging. J Invest Dermatol 135, 1752-1762 (2015). 456 
 457 
13. Patel, A.A. et al. The fate and lifespan of human monocyte subsets in steady state 458 
and systemic inflammation. The Journal of experimental medicine 214, 1913-1923 459 
(2017). 460 
 461 
  ES Chambers et al 
 
30 | P a g e  
 
14. Ziegler-Heitbrock, L. et al. Nomenclature of monocytes and dendritic cells in blood. 462 
Blood 116, e74-80 (2010). 463 
 464 
15. Tamoutounour, S. et al. Origins and functional specialization of macrophages and of 465 
conventional and monocyte-derived dendritic cells in mouse skin. Immunity 39, 925-466 
938 (2013). 467 
 468 
16. Pereira, B.I. et al. Senescent cells evade immune clearance via HLA-E-mediated NK 469 
and CD8(+) T cell inhibition. Nat Commun 10, 2387 (2019). 470 
 471 
17. Dimri, G.P. et al. A biomarker that identifies senescent human cells in culture and in 472 
aging skin in vivo. Proc Natl Acad Sci U S A 92, 9363-9367 (1995). 473 
 474 
18. Ressler, S. et al. p16INK4A is a robust in vivo biomarker of cellular aging in human 475 
skin. Aging Cell 5, 379-389 (2006). 476 
 477 
19. Campisi, J. Aging, cellular senescence, and cancer. Annu Rev Physiol 75, 685-705 478 
(2013). 479 
 480 
20. Dean, J.L., Brook, M., Clark, A.R. & Saklatvala, J. p38 mitogen-activated protein 481 
kinase regulates cyclooxygenase-2 mRNA stability and transcription in 482 
lipopolysaccharide-treated human monocytes. J Biol Chem 274, 264-269 (1999). 483 
 484 
21. Mestre, J.R. et al. Redundancy in the signaling pathways and promoter elements 485 
regulating cyclooxygenase-2 gene expression in endotoxin-treated 486 
macrophage/monocytic cells. J Biol Chem 276, 3977-3982 (2001). 487 
 488 
22. Kalinski, P. Regulation of immune responses by prostaglandin E2. Journal of 489 
immunology 188, 21-28 (2012). 490 
 491 
23. Guan, Z., Buckman, S.Y., Pentland, A.P., Templeton, D.J. & Morrison, A.R. Induction 492 
of cyclooxygenase-2 by the activated MEKK1 --> SEK1/MKK4 --> p38 mitogen-493 
activated protein kinase pathway. J Biol Chem 273, 12901-12908 (1998). 494 
 495 
24. Chen, H. et al. Elevated COX2 expression and PGE2 production by downregulation 496 
of RXRalpha in senescent macrophages. Biochem Biophys Res Commun 440, 157-497 
162 (2013). 498 
 499 
25. Okano, M. et al. E prostanoid 2 (EP2)/EP4-mediated suppression of antigen-specific 500 
human T-cell responses by prostaglandin E2. Immunology 118, 343-352 (2006). 501 
 502 
26. Baratelli, F. et al. Prostaglandin E2 induces FOXP3 gene expression and T 503 
regulatory cell function in human CD4+ T cells. Journal of immunology 175, 1483-504 
1490 (2005). 505 
 506 
27. Sharma, S. et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of 507 
FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. 508 
Cancer Res 65, 5211-5220 (2005). 509 
  ES Chambers et al 
 
31 | P a g e  
 
 510 
28. Vukmanovic-Stejic, M. et al. Varicella zoster-specific CD4+Foxp3+ T cells 511 
accumulate after cutaneous antigen challenge in humans. Journal of immunology 512 
190, 977-986 (2013). 513 
 514 
29. Nakanishi, M. & Rosenberg, D.W. Multifaceted roles of PGE2 in inflammation and 515 
cancer. Semin Immunopathol 35, 123-137 (2013). 516 
 517 
30. MacKenzie, K.F. et al. PGE(2) induces macrophage IL-10 production and a 518 
regulatory-like phenotype via a protein kinase A-SIK-CRTC3 pathway. Journal of 519 
immunology 190, 565-577 (2013). 520 
 521 
31. Zelenay, S. et al. Cyclooxygenase-Dependent Tumor Growth through Evasion of 522 
Immunity. Cell 162, 1257-1270 (2015). 523 
 524 
32. Watanabe, R. et al. Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses 525 
T cell immunity. J Clin Invest 127, 2725-2738 (2017). 526 
 527 
33. Sammicheli, S. et al. Inflammatory monocytes hinder antiviral B cell responses. Sci 528 
Immunol 1 (2016). 529 
 530 
34. Chen, G. et al. Clinical and immunological features of severe and moderate 531 
coronavirus disease 2019. J Clin Invest (2020). 532 
 533 
35. Liao, M. et al. Single-cell landscape of bronchoalveolar immune cells in patients with 534 
COVID-19. Nature medicine (2020). 535 
 536 
36. Pence, B.D. et al. Relationship between systemic inflammation and delayed-type 537 
hypersensitivity response to Candida antigen in older adults. PLoS One 7, e36403 538 
(2012). 539 
 540 
37. Fourati, S. et al. Pre-vaccination inflammation and B-cell signalling predict age-541 
related hyporesponse to hepatitis B vaccination. Nat Commun 7, 10369 (2016). 542 
 543 
38. Muyanja, E. et al. Immune activation alters cellular and humoral responses to yellow 544 
fever 17D vaccine. J Clin Invest 124, 3147-3158 (2014). 545 
 546 
39. Parmigiani, A. et al. Impaired antibody response to influenza vaccine in HIV-infected 547 
and uninfected aging women is associated with immune activation and inflammation. 548 
PLoS One 8, e79816 (2013). 549 
 550 
40. Mannick, J.B. et al. mTOR inhibition improves immune function in the elderly. Sci551 
Transl Med 6, 268ra179 (2014). 552 
 553 
41. Hahn, T. et al. Short-term dietary administration of celecoxib enhances the efficacy of 554 
tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer. Int J 555 
Cancer 118, 2220-2231 (2006). 556 
 557 
  ES Chambers et al 
 
32 | P a g e  
 
Figure legends: 558 
Figure 1: Recruitment of monocytes to sites of injection in the skin 559 
A, Schematic of visits for blood and skin sampling by old (>65 years) and young (<40 years) 560 
donors taking part in this study. B, representative image of a skin section stained with DAPI 561 
(white), CCR2 (red) and CD14 (blue), pink arrows indicate CD14 and CCR2 co-staining and 562 





 cells in C, saline-injected (n=9 young and n=13 old biologically independent 564 
individuals). D, cumulative data showing the frequency of monocytes in normal (N) and 565 
Saline (6 hours; S6) in skin biopsies collected from young (white; n=6) and old (grey; n=5) 566 
individuals as assessed by flow cytometry. Cells were identified as mononuclear phagocytes 567 
if they were CD45
+









 cells were assessed as a percentage of CD45+ cells present 569 






 cells in VZV-570 
injected skin a (n=5 Young and n=5 old biologically independent individuals) as compared to 571 
normal skin. F, Correlation between delta change in number of CD14
+
 cells in the skin after 572 
saline injection as compared to normal skin in relation to their VZV clinical response. Old 573 
donors are in black filled circles (VZV score 0-3; n=13), Old responders VZV clinical score 574 
4; n=6) and young donors (n=9) are in open black square. C and E shown as mean ± SEM.575 
C-E analysed with an unpaired t-test and F analysed by Spearmans correlation.  576 
 577 
Figure 2: Monocyte chemoattractant expression after saline injection in the skin  578 
A, representative image of normal and saline injected skin stained with CD31 (green) and 579 
CD62E (red) and B, cumulative data showing the frequency of CD31
+
 endothelial loops 580 
expressing CD62E in young  (white; n=6) and old (grey; n=12). C, heat map showing 581 
expression of monocyte chemokines in normal then saline injected skin of young and old 582 
donors and D, cumulative data showing number of CCL2
+
 cells in young (white n=7) and old 583 
donors (grey; n=9) and E, representative image, arrows indicate double positive cells and F, 584 




 cells in normal and saline injected old skin 585 
(n=10). G, representative image showing DAPI (white), CCL2 (green), p16 (red) and FSP1 586 













 cells (n=10). I, correlation between the number of senescent fibroblast in 588 
normal skin (defined as being Telomere associated  DNA damage foci [TAF] positive;) and 589 
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the change in CD14
+
 monocytes after saline injection in old (black circles; n=3), old 590 
responders (red circles; n=2) and young (open squares; n=8) B, D, F and H, assessed with 591 






 monocytes inhibit T cell proliferation via PGE
2
 594 
A, Heatmap showing the expression of genes associated with inhibitory mechanisms in 595 
normal and saline injected of old and young donors B, representative staining of DAPI 596 
(white), COX2 (red) and CD14 (blue) in normal and saline injected skin and C, cumulative 597 




 cells in normal 598 
and saline injected skin (n=9). E, Monocytes were negatively isolated from the peripheral 599 
blood and cultured with and without LPS for 3 hours then subsequently co-cultured with 600 
autologous T cells (pre-labelled with CellTrace Violet) that were activated with plate-bound 601 
CD3 and IL-2, proliferation was assessed at day 4. A representative flow plot of CellTrace 602 
violet dilution in CD4
+
 T cells co-cultured with unstimulated and stimulated monocytes is 603 
shown in E and F, cumulative data showing percent of cells divided (n=10). A similar co-604 
culture experiment was performed in the presence or absence of the COX2 inhibitor NS-398 605 
(n=11) G, and H, or the EP4 receptor inhibitor MF498 (n=5) I, and J,. Control is unstimulated 606 
monocytes co-cultured with T cells in the presence of drug. Each data point within each 607 
figure is a biologically independent experiment. F, shown as mean ± SEM. In C,D, F, H and608 
J analysed with a paired t-test.  609 
 610 




 cell proliferation. 611 
A, representative staining of CD4 of eight independent donors (green), CD69 (red) and EP4 612 




 cells which co-express EP4. B, 613 




 cells and CD14
+
 monocytes 614 
(blue) and C, cumulative data showing distance of CD14
+
 monocytes from T
RM
 in normal and 615 
saline injected skin from older adults (n=7). Monocytes were negatively isolated from the 616 
peripheral blood and cultured with and without LPS  for 3 hours then subsequently co-617 
cultured with skin T
RM
 cells (pre-labelled with CellTrace Violet), which were collected from 618 
suction blisters (representative image in D) then activated with  plate-bound CD3 and IL-2 619 
and proliferation was assessed at day 4. E, representative flow plot of CellTrace violet 620 
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 cells co-cultured with unstimulated (red line) or stimulated (blue line) 621 




  proliferation in the presence of stimulated or 622 
unstimulated monocytes, assessed at day 4 (n=4). C, and F, were analysed with a paired t-623 
test.  624 
 625 
Figure 5: Reduced inflammatory monocyte recruitment to the skin by Losmapimod 626 
pre-treatment 627 
A, Losmapimod clinical study diagram. Black arrows indicate study visits, red arrows indicate 628 
blood samples collected and blue arrows indicate skin biopsies taken. B, Colour coding of 629 
the clinical response of each individual after VZV challenge both before and after 630 
Losmapimod pre-treatment (pink/brown). Further colour coding was introduced to identify the 631 
extent of improvement where dark green identifies the biggest improvement and white 632 
shows no improvement in the skin. C, This coding was used in conjunction with the 633 
transcriptomic signatures in normal and saline injected skin before and after Losmapimod 634 
treatment. The top 30 genes upregulated in saline injected skin as compared to normal skin 635 
before pre- Losmapimod. D, Fold change of CCL2
+
 cells (n=7 biologically independent 636 




 that express p16 in saline injected pre- and post-637 
Losmapimod treatment (n=7 biologically independent individuals). F, fold change CD14
+
 cell 638 
in the skin in response to saline injection (n=9 biologically independent individuals) and G, 639 
number of CD14
+
 monocytes in VZV injected skin (6 hours after injection; n=5 biologically 640 
independent individuals) pre- and post-Losmapimod treatment. Significance in D-G 641 
assessed using a paired t-test.  642 
 643 
Figure 6: Losmapimod restores T cell function by inhibiting monocyte COX2 and PGE
2
644 
production  645 
Monocytes were negatively isolated from the peripheral blood and cultured with and without 646 
LPS and in the presence or absence of Losmapimod for 3 hours, pellets were collected and 647 
western blot performed A, representative blot of phospho-p38 MAP Kinase (p-p38), total p38 648 
MAP Kinase (p38), COX2 and GAPDH, full scans can be seen as source data fig.6. B,649 
cumulative data of COX2 expression  assessed by western blot relative to GAPDH (n=3) 650 
and C, Prostaglandin E2 (PGE
2
) production (n=6). Monocytes were negatively isolated from 651 
the peripheral blood and stimulated with LPS (blue) and without LPS (red) or with LPS in the 652 
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presence of Losmapimod (white) for 3 hours then subsequently co-cultured with autologous 653 
T cells (pre-labelled with CellTrace Violet) in the presence of plate-bound CD3 and IL-2 654 
proliferation was assessed at day 4. D, A representative flow plot of CellTrace violet dilution 655 
in CD4+ T cells co-cultured with unstimulated monocytes in the presence of Losmapimod 656 
(control; red) or stimulated monocytes (red) or stimulated monocytes in the presence of 657 
Losmapimod (black), and E, cumulative data showing percent of cells divided (n=6). F, fold 658 




 cells between normal and saline injected skin before 659 
and after Losmapimod treatment (n=8). B, and C, shown as mean ± SEM and analysed by a 660 
one-way ANOVA with Tukeys multiple comparison test and E, and F, analysed with a 661 
Wilcoxon matched-pairs signed rank test  662 
 663 
Figure 7: Losmapimod treatment increases VZV induced T cell responses in the skin 664 
A, VZV clinical score and B, serum CRP concentrations in all donors pre- and post-665 
Losmapimod treatment (n=42). Representative images of CD11c (blue) and Ki67 (green) 666 
and  C, CD4 (red) or D, CD8 (red) staining at 7 days after VZV challenge pre- and post- 667 
Losmapimod. Cumulative data of E, CD4
+




 staining, G, CD8
+





 and I, CD11c
+
 staining after VZV challenge in responders pre- and post-669 
Losmapimod. Six hours (6h; n=5), 48 hours (48h; n=4) and Day 7 (n=7). E-I shown as mean 670 
+ SEM and analysed by a wilcoxon-matched pairs test and   671 
 672 
Figure 8: Schematic model of monocyte inhibition of cutaneous immunity in older 673 
adults674 
In older adults the mild damage induced by injection (of air, saline or VZV) results in 675 
production of CCL2 from senescent fibroblasts and recruitment of monocytes into the skin 6 676 
hours post injection. The recruited monocytes inhibit TRM proliferation via upregulation of 677 
COX2 and subsequent production of the lipid mediator Prostaglandin E2 (PGE2). The 678 
treatment of older adults with the p38 MAPK inhibitor, Losmapimod, results in reduced CCL2 679 
production from the senescent fibroblasts and reduced monocyte infiltration. In addition, p38 680 
MAPK is upstream of COX2 signalling, therefore the treatment with Losmapimod also 681 
inhibits COX2 upregulation and reduced PGE2 production. This significantly increases the T 682 
cell response to VZV in the skin of older subjects 683 
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Materials and Methods: 684 
Study design:  685 
The investigation of healthy young (under 40 yrs) and old subjects (65 yrs and over) was 686 
approved by the Ethics Committee Queens Square (London) and by institutional review 687 
board (UCL R&D). Individuals with history of neoplasia, immunosuppressive disorders or 688 
inflammatory skin disorders were excluded as described in detail elsewhere9 (see 689 
Supplementary Table 1 for donor characteristics). In brief, we excluded individuals with co-690 
morbidities that are associated with significant internal organ or immune dysfunction 691 
including heart failure, severe COPD, diabetes mellitus and rheumatoid arthritis and 692 
individuals on immunosuppressive regimes for the treatment of autoimmune or chronic 693 
inflammatory diseases (e.g. oral glucocorticoids, methotrexate, azathioprine and 694 
cyclosporin). In addition, individuals with history of liver disease or elevated liver 695 
transaminases (>1.5 times the upper limit of normal), or who had abnormal ECG. All 696 
volunteers provided written informed consent and study procedures were performed in 697 
accordance with the principles of the declaration of Helsinki. No statistical methods were 698 
used to pre-determine sample sizes of this section of our data, but our sample sizes are 699 
similar to those reported in previous publications 8, 9, 12, 28. 700 
For the study involving Losmapimod, we recruited 42 healthy older adults (>65 years); 19 701 
males and 23 females with a mean age of 70.7 years old (95% CI 69-72.3 years old). A 702 
power calculation was performed to establish effect on change in clinical score, and we 703 
assumed an alpha level of 0.05 (2-sided) and a power of 0.90 was considered desirable. 704 
VZV skin test was performed and biopsies collected at different time points as described9. 705 
Only Caucasian European individuals were included in the study and Any individual with a 706 
clinical score >3 was excluded from the study as described previously9.  Two to three 707 
months after the first VZV skin challenge the same volunteers received 15 mg Losmapimod 708 
(GW856553) twice a day for 4 days (provided by GlaxoSmithKline [GSK] under a Medical 709 
Research Council Industrial Collaboration Agreement). We have found previously that the 710 
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first VZV challenge did not significantly boost the response to re-challenge of the same 711 
individuals after 2-3 months9. Losmapimod 15 mg twice a day dose used in this study was 712 
chosen on the basis of the PK, PD and safety profiles of Losmapimod observed in GSK 713 
Phase I and II studies42. These individuals were then re-challenged with VZV skin antigen 714 
and biopsies were collected at the same timepoints as before Losmapimod treatment. 715 
Clinical scores after VZV injection were performed by two independent researchers and an 716 
average reading was recorded. Serum CRP levels were measured with a high sensitivity 717 
assay (pre- and post-Losmapimod). No adverse side effects were observed in our study 718 
group in response Losmapimod pre-treatment for 4 days.  719 
We were advised by the UKs Medicines and Healthcare products Regulatory Agency 720 
(MHRA) that it was not a Clinical Trial of an Investigational Medicinal Product (IMP) as 721 
defined by the EU Directive 2001/20/EC. As this experimental medicine study was designed 722 
to test a hypothesis in humans in vivo and not to determine the therapeutic outcome or 723 
efficacy of the drug Losmapimod for patient benefit. Therefore no randomisation was 724 
performed. The life sciences reporting summary of this work can be found in the 725 
supplementary information. 726 
 727 
Skin tests and punch biopsy:  728 
VZV antigen (BIKEN, The Research Foundation for Microbial Diseases of Osaka University, 729 
Japan) or 0.9% saline solution or an equal volume of air was injected intradermally into sun 730 
unexposed skin of the medial proximal volar forearm as per manufacturers instructions. 731 
Induration, palpability and the change in erythema from baseline were measured and scored 732 
on day 2 or 3 as described previously11. A clinical score (range 0-10) based on the 733 
summation of these parameters was then calculated. Donor characteristics can be found in 734 
Supplementary Table 1. 735 
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Two punch biopsies (5 mm diameter) were collected from normal (unmanipulated skin) and 736 
either saline injected or VZV injected site (at time-points as indicated). Biopsies were frozen 737 
in OCT (optimal cutting temperature compound; Bright Instrument Company Ltd). 6 m 738 
sections were cut and left to dry overnight and then fixed in ethanol and acetone and stored 739 
at -80ºC. 740 
741 
Immunofluorescence:  742 
Sections were stained with optimal dilutions of primary antibodies and followed by relevant 743 
secondary antibody conjugated to various fluorochromes as described (Supplementary 744 
Table 2). Skin sections were imaged on the AxioScan Z1 slide scanner and analysed using 745 
Zen Blue (Zeiss) For normal and 6 hour injected skin and endothelium counts, total cells in 746 
the upper dermis were counted and numbers of cells per mm2 were calculated. Images were 747 
taken from the upper dermis, an example of which is shown in Figure 1. For VZV injected 748 
skin (days 2-7) the number of cells in five of the largest perivascular infiltrates present in the 749 
upper and mid dermis were selected for analysis and an average was calculated as 750 
described previously10. Staining for telomere-associated H2AX foci (TAF) were carried out 751 
as described previously16. Counting was performed manually, the data was blinded to the 752 
assessor to avoid any bias and where multiple skin sections from one sample were 753 
assessed the average of the counts was used. 754 
 755 
Skin Biopsy digestion for flow cytometric analysis:  756 
Skin biopsies (5 mm) were taken from normal and saline injected skin (6 or 24-hours post-757 
injection) and disaggregated by overnight incubation (37oC) in either 0.8 mg/ml collagenase 758 
IV (Sigma Aldrich) with 20% FCS or a whole skin digestion kit from Miltenyi Biotec. Single 759 
cell suspensions were obtained and subsequently stained with the cell surface antibodies as 760 
listed in Supplementary Table 3. Samples were assessed by flow cytometric analysis on a 761 
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BD Fortessa using FACSDIVA software, and subsequently analysed using FlowJo Version X 762 
(BD Biosciences). 763 
Unbiased representations of multi-parameter flow cytometry data were generated using the 764 
t-distributed stochastic neighbour embedding (tsne) algorithm. The R package Rtsne 765 
available on CRAN (github.com/jkrijthe/Rtsne) was used to perform the Barnes Hut 766 
implementation of t-SNE on flow cytometry data. FlowJo software was used to export events 767 
of interest (in fcs format) for each sample. After using the Bioconductor flowCore R 768 
package to import fcs file data and the Logicle transform to scale the data similarly to that 769 
displayed in FlowJo, 3000 HLA-DR+ events from each samples analysed in parallel were 770 
merged and the relevant fluorescent parameters were used. 771 
772 
RNAseq analysis of skin:  773 
Three 3 mm punch biopsies were collected from each volunteer: VZV injection site at 48 774 
hours post-injection, saline injection site at 6 hours post-injection and normal (un-injected) 775 
skin as a control. Biopsies were immediately frozen in RNAlater. Frozen tissue was 776 
homogenized, and total RNA was extracted from bulk tissue homogenates using RNeasy 777 
Mini Kit (Qiagen). Library preparation for RNAseq was performed using the Kappa 778 
Hyperprep kit (Roche Diagnostics) and sequencing was performed by the Pathogens 779 
Genomic Unit (UCL) on the Illumina Nextseq 500 (Illumina) using the NextSeq 500/550 High 780 
Output 75 cycle kit (Illumina) according to manufacturers instructions, giving 15-20 million 781 
41bp paired end reads per sample. Reads were aligned to Genome Reference Consortium 782 
Human Build 38 (GRCh38) using Hisat243. Samtools was used to select for reads with paired 783 
mates. Transcript assembly was carried out using StringTie44, with gene-level Fragments per 784 
Kilobase of transcript per Million mapped read (FPKM) generated using Ballgown45. The 785 
RNAseq data has been deposited on Gene Expression Omnibus (Accession Number: 786 
GSE130633).  787 
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Statistical comparisons were made on gene count estimates generated by StringTie. Genes 788 
with low expression (<1 count per million mapped reads in 95% of the samples) or short 789 
transcript lengths (<200 nucleotides for the longest transcript) were removed. The count 790 
matrix was normalised using the TMM method in edgeR (version 3.22.5)46, followed by 791 
contrast fit with voom in limma (version 3.36.5)47, treating the subject ID as a blocking 792 
variable. Statistically significant differentially expressed genes were with an adjusted p-value 793 
of less than 0.05 and expression change of greater than 2-fold up or down, were considered 794 
to be statistically significant.  795 
Gene correlation networks (GCN) were constructed and visualised using Graphia 796 
Professional (Kajeka Ltd, version 2.1; , https://graphia.app/). Genes without a known HUGO 797 
gene nomenclature, or with expression < 1 FPKM for all samples, were removed from the 798 
co-expression network analysis. The Markov Cluster Algorithm (MCL) was used to define the 799 
network clusters using an inflation value of 2.2. Saline-specific gene expression was 800 
generated using the average expression (FPKM) for genes that are significant in  801 
Pre-Losmapimod in saline-injected skin as compared to normal (Fold change>2 and 802 
p<0.05). RNAseq data that support the findings of this study have been deposited in NCBI 803 
Gene Expression Omnibus accession code GSE130633. 804 
 805 
Leukocyte isolation from peripheral blood: 806 
PBMC were isolated by density centrifugation using Ficoll-Paque (Amersham Biosciences). 807 
CD4+ T cells were purified by positive selection and monocytes were isolated by negative 808 
selection according to the manufacturers instructions (Miltenyi Biotec).  809 
 810 
Monocyte and T cells co-culture: 811 
Monocytes (1x106/ml) were cultured in the presence of LPS (1ng/ml) and/or NS-398 (1µM) 812 
at 37oC with 5% CO2. Monocytes were collected three hours post incubation and washed 813 
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once to remove residual LPS. These  cells  were pre-incubated with inhibitors NS-398 (1µM) 814 
or Losmapimod (3µM) where indicated. CD4+ T cells were labelled with CellTrace Violet 815 
(Invitrogen) according to the manufacturers instructions prior to culture. CD4+ T cells  and 816 
monocytes (unstimulated or LPS stimulated) were co-cultured at different ratios, in the 817 
presence of plate-bound CD3 (1µ/ml) and IL-2 (50IU/ml) and MF-498 (1µM) as indicated (at 818 
37oC with 5% CO2) for four days. 819 
For experiments involving co-culture of monocytes with skin TRM cells, two suction blisters 820 
were formed over uninjected skin, as described previously11. Cells were collected from the 821 
blister the following day and incubated on plastic for 3 hours, to remove mononuclear 822 
phagocytes. Cell suspensions (predominantly CD4+ T cells) were removed and labelled with 823 
CellTrace Violet and co-cultured with unstimulated or LPS stimulated monocytes as 824 
described above. 825 
 826 
T cell proliferation assessment: 827 
Samples were collected on day 4 post-culture and stained for the following: CD3 (UCHT1), 828 
CD4 (RPA-T4; BD Biosciences) and Zombie NIR Fixable Viability Kit (Biolegend). 829 
Samples were assessed by flow cytometric analysis on a BD Fortessa using FACSDIVA 830 
software, and subsequently analysed using FlowJo Version X (BD Biosciences). 831 
 832 
Western Blot analysis: 833 
Cell pellets were harvested and lysed with RIPA buffer (Sigma-Aldrich) supplemented with 834 
protease and phosphatase inhibitors (Cell Signalling) for 30 min on ice. Cell lysates were 835 
diluted in SDS sample buffer with reducing agent (NuPage, Life Technologies) and boiled for 836 
5 min at 95 °C. Samples were separated by protein electrophoresis at 120 V for 2 h using 837 
10% Bis-Tris pre-cast gels (NuPage) and transferred overnight at 4°C onto Hybond-P PVDF 838 
membranes (GE Healthcare). After blocking in ECL blocking agent (GE Healthcare), 839 
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membranes were probed with primary antibodies overnight at 4°C. Primary antibodies used 840 
were COX2 (ab15191; Abcam), phospho-p38 MAPK (T180/Y182; 9211), and p38 MAP 841 
Kinase (9212), GAPDH (2118; Cell Signalling). The membrane was washed and incubated 842 
with HRP-conjugated secondary antibodies (GE Healthcare, 1:4000) for 1 h at room 843 
temperature. Antibodies were detected using the ECL detection kit (GE Healthcare). Prior to 844 
re-probing with different antibodies, membranes were stripped at room temperature with 845 
agitation using Restore stripping buffer (Thermo Scientific). Protein bands were quantified 846 
using ImageJ software. The integrated density of each band was normalised to GAPDH 847 
using the gel analysis function of ImageJ. 848 
 849 
Dermal Fibroblast isolation and culture: 850 
Dermal fibroblasts were isolated and cultured as described previously16. Senescence was 851 
induced in these cells by exposure to X-ray radiation at a total dose of 10Gy at a rate of 852 
5Gy/min. Irradiated cells were cultured for a further 10-28 days to allow for senescence to 853 
develop. Senescence was confirmed by staining for SA -galactosidase (Cell signalling). 854 
Non-senescent (early passage number 4-10) and senescent fibroblasts were cultured in a 855 
48-well plate at 20 × 104 cells per well in the presence of absence of Losmapimod (3µM), 856 
and supernatants were collected at 3 and 24 hours. 857 
 858 
Assessment of supernatants: 859 
Cytokine concentration in culture supernatants were assessed by cytometric bead array 860 
(CBA) according to the manufacturer's protocol. Samples were analysed using a BD Verse 861 
flow cytometer (BD Biosciences). The lower limit of detection for each analyte was 1.5pg/mL. 862 
For assessment of PGE2 production from monocyte cultures with a Prostaglandin E  Direct 863 
Biotrak Assay was used according to the manufacturers protocol (Fisher scientific). 864 
865 
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Statistics:866 
Statistical analysis was performed using GraphPad Prism version 8.00 (GraphPad 867 
Software). Data was assessed for normality and the subsequent appropriate statistical two-868 
sided statistical test was performed as indicated in the legend of each figure. 869 
 870 
Code availability statement: Scripts used in the RNA-seq analysis can be found on the 871 
GitHub repository at https://github.com/barbarashih/arise_losmapimod 872 
Data availability statement: RNAseq data that support the findings of this work, can be 873 
found RNAseq data that support the findings of this study have been deposited in NCBI 874 
Gene Expression Omnibus, accession code GSE130633. The rest of the data that support 875 
the findings of this study are available as source data. 876 
 877 
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